Table I.
Characteristics of patient with psoriasis and matched healthy controls
| Variable | Psoriasis (N = 23) | Healthy controls (N = 15) | P value |
|---|---|---|---|
| Demographic and clinical characteristics | |||
| Age, y | 42.0 ± 14 | 40.6 ± 14 | .71 |
| Male sex | 11 (48) | 8 (53) | .74 |
| Hyperlipidemia | 1 (4) | 0 | .41 |
| Type 2 diabetes mellitus | 0 | 0 | >.99 |
| Body mass index, kg/m2 | 27 (24–30) | 25 (23–30) | .58 |
| Hypertension | 0 | 0 | >.99 |
| Current smoker | 0 | 0 | >.99 |
| Lipid treatment | 0 | 0 | >.99 |
| Clinical and laboratory values | |||
| Total cholesterol, mg/dL | 173 ± 26 | 156 ± 26 | .21 |
| HDL cholesterol, mg/dL | 49 ± 14 | 51 ± 12 | .63 |
| LDL cholesterol, mg/dL | 108 (75–112) | 84 (68–115) | .44 |
| Triglycerides, mg/dL | 85 (59–113) | 65 (56–103) | .24 |
| Framingham risk score, median (IQR), % | 2.3 (1.4–4.2) | 1.7 (1.0–3.0) | .21 |
| hs-CRP, median (IQR), mg/L | 1.8 (0.5–4.1) | 1.4 (0.5–1.5) | .41 |
| Psoriasis severity | |||
| Psoriasis Area and Severity Index score, median (IQR) | 4.8 (2.7–10.8) | N/A | N/A |
| Systemic or biologic treatment | 11 (49) | N/A | N/A |
| Psoriasis duration, median (IQR), y | 18.5 (10–22.5) | N/A | N/A |
| Proinflammatory cytokines | |||
| CCL20, NPX | 6.3 ± 1.4 | 5.2 ± 0.7 | .009 |
| IL-17A, NPX | 2.5 ± 2.1 | 1.2 ± 1.0 | .03 |
| IL-6, NPX | 4.9 ± 1.6 | 4.2 ± 0.7 | .08 |
Data are presented as mean ± standard deviation or No. (%) unless otherwise stated. Significant at P < .05.
CCL20, Chemokine ligand 20; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; IQR, interquartile range; LDL, low-density lipoprotein; N/A, not applicable; NPX, normalized expression units on a log2 scale.